Product Description
Mechanisms of Action: ADORA1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Heart Failure
Phase 2: Heart Failure|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
PROTECT-2 | P3 |
Completed |
Heart Failure |
2009-07-01 |
|
PROTECT-1 | P3 |
Completed |
Heart Failure |
2009-07-01 |
|
2008-002209-38 | P2 |
Terminated |
Heart Failure|Kidney Diseases |
2009-03-06 |
|
MK7418-503 | P2 |
Completed |
Heart Failure |
2009-03-01 |